204 related articles for article (PubMed ID: 38550594)
21. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M; Du Rusquec P; Romano E
Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH; Sadri M; Najafi A; Rahimi A; Baghernejadan Z; Khorramdelazad H; Falak R
Front Immunol; 2022; 13():1018962. PubMed ID: 36389779
[TBL] [Abstract][Full Text] [Related]
23. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract][Full Text] [Related]
24. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
25. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
26. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Mullinax JE; Egger ME; McCarter M; Monk BJ; Toloza EM; Brousseau S; Jagasia M; Sarnaik A
Cancer J; 2022 Jul-Aug 01; 28(4):285-293. PubMed ID: 35880938
[TBL] [Abstract][Full Text] [Related]
27. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
28. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
29. Cellular Therapy and Cytokine Treatments for Melanoma.
Borgers JSW; Haanen JBAG
Hematol Oncol Clin North Am; 2021 Feb; 35(1):129-144. PubMed ID: 33759770
[TBL] [Abstract][Full Text] [Related]
30. The Landscape of Adoptive Cellular Therapies in Ovarian Cancer.
Davis L; Miller RE; Wong YNS
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835509
[TBL] [Abstract][Full Text] [Related]
31. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Mayor P; Starbuck K; Zsiros E
Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
[TBL] [Abstract][Full Text] [Related]
32. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.
Watanabe K; Nishikawa H
Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779
[TBL] [Abstract][Full Text] [Related]
33. Adoptive Immunotherapy beyond CAR T-Cells.
Titov A; Zmievskaya E; Ganeeva I; Valiullina A; Petukhov A; Rakhmatullina A; Miftakhova R; Fainshtein M; Rizvanov A; Bulatov E
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670139
[TBL] [Abstract][Full Text] [Related]
34. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
[TBL] [Abstract][Full Text] [Related]
35. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
36. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
37. Genetic Modification of Tumor-Infiltrating Lymphocytes
Weinstein-Marom H; Gross G; Levi M; Brayer H; Schachter J; Itzhaki O; Besser MJ
Front Immunol; 2020; 11():584148. PubMed ID: 33488585
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
39. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.
Diaz-Cano I; Paz-Ares L; Otano I
Int Rev Cell Mol Biol; 2022; 370():163-192. PubMed ID: 35798505
[TBL] [Abstract][Full Text] [Related]
40. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
